The urgent need for effective cancer treatments,particularly for advanced and relapsed cases in which standard therapies are inadequate,has spurred the development of innovative therapeutic drugs1,2.Among the strategi...The urgent need for effective cancer treatments,particularly for advanced and relapsed cases in which standard therapies are inadequate,has spurred the development of innovative therapeutic drugs1,2.Among the strategies to expedite drug development,the use of single-arm trials(SATs)is emerging as a promising avenue with substantial potential to shorten drug approval timelines and accelerate market entry.展开更多
According to the official website of China’s National Medicines and Pharmaceutical Administration(NMPA),a total of 87 novel drugs were approved in China in 2023,with targeted drugs accounting for 67.8%of the total,am...According to the official website of China’s National Medicines and Pharmaceutical Administration(NMPA),a total of 87 novel drugs were approved in China in 2023,with targeted drugs accounting for 67.8%of the total,amounting to 59 drugs(Fig.1a;Table 1)[https://www.nmpa.gov.cn/yaopin/ypjgdt/index.html].Notably,domestic innovation is flourishing,with five first-in-class drugs,including Glumetinib,a c-Met inhibitor from Haihe Biopharma;Leritrelvir,a 3CL protease inhibitor from Raynovent;Anaprazole,a proton pump inhibitor from Xuanzhu Biopharm;Pegol-Sihematide,an EPO drug from Hansoh Pharma;and Zuberitamab from BioRay Biopharmaceutical Co.,Ltd.Additionally,the world’s first allosteric inhibitor targeting TYK2,Sotyktu(deucravacitinib),has been approved for the treatment of psoriasis and Selumetinib,a MEK inhibitor co-developed by AstraZeneca and Merck Sharp&Dohme(MSD),became the first approved drug in China for the treatment of neurofibromatosis type I(NF1).Beyond these drugs,the approval of novel drug types such as CAR-T cell products,siRNA,monoclonal antibodies,dual antibodies,and ADCs in China is a significant development in the country’s pharmaceutical industry(Fig.1a).展开更多
Historically,"big pharma"did most central nervous system drug discovery R&D in-house.Yet,in modern times their"management reductionism"resulted in disappointing pipelines and pharma resided to(...Historically,"big pharma"did most central nervous system drug discovery R&D in-house.Yet,in modern times their"management reductionism"resulted in disappointing pipelines and pharma resided to(late)development,regulatory approval,and marketing(Thong,2015).This had significant consequences for financing and executing research,resulting in a larger role for funding by governments and patient-organizations and a shift of research to academia(Mazzucato,2013).展开更多
Mongolia,a key partner in the Belt and Road Initiative,is fully dedicated to fostering regional cooperation and connectivity.Standardization has emerged as a vital field with far-reaching influence for regional trade ...Mongolia,a key partner in the Belt and Road Initiative,is fully dedicated to fostering regional cooperation and connectivity.Standardization has emerged as a vital field with far-reaching influence for regional trade cooperation.This paper makes an in-depth analysis of the standards approved in Mongolia in 2021 and 2022,offering a fresh perspective of the past two years’standardization development in the country.The primary objective is to present an updated account of Mongolia’s standardization efforts and to facilitate regional cooperation and exchange in standardization.展开更多
The authors regret that the name of the ethic committee that approved the study and the reference number was omitted from the published paper.In this research,all animal experiments were performed in accordance with t...The authors regret that the name of the ethic committee that approved the study and the reference number was omitted from the published paper.In this research,all animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals(US National Institutes of Healh)and were approved by the Animal Welfare and Ethical Committee of Hebei University(No.IACUC-2020XG021,Baoding,China).展开更多
In the summer of 2023,two US restaurants added a novel item to their menus:chicken grown in a lab(Fig.1)[1,2].The first to receive regulatory approval for commercial sale,the lab-grown—or"cultivated"—meat ...In the summer of 2023,two US restaurants added a novel item to their menus:chicken grown in a lab(Fig.1)[1,2].The first to receive regulatory approval for commercial sale,the lab-grown—or"cultivated"—meat starts as a few real chicken cells that are grown in vats of liquid and nutrients until they become pieces large enough to shape into nuggets and strips.展开更多
The publisher would like to draw the reader's attention to the following errors.Ethics approval statements were not included in the published version of the following articles that appeared in previous issues of G...The publisher would like to draw the reader's attention to the following errors.Ethics approval statements were not included in the published version of the following articles that appeared in previous issues of Grain&Oil Science and Technology.The authors were contacted after publication to request ethical approval statements for the following articles.展开更多
State Administration for Market Regulation and National Standardization Administration of China have approved the following 328 national standards and 3 national standards with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 423 voluntary national standards and 2 national standards with amendment.
State Administration for Market Regulation and National Standardization Administration of China have approved the following 258 national standards in foreign language version.
State Administration for Market Regulation and National Standardization Administration of China have approved the following 24 mandatory national standards and 2 mandatory national standards with amendment.
State Administration for Market Regulation and National Standardization Administration of China have approved the following 20 national standards and 1 national standard with amendment.
The 46th Annual Meeting of ISO was held in Cartagena,Colombia.The event was attended by more than 700 representatives of ISO members,as well as international and regional organizations,with more than2,200 representati...The 46th Annual Meeting of ISO was held in Cartagena,Colombia.The event was attended by more than 700 representatives of ISO members,as well as international and regional organizations,with more than2,200 representatives participating in the series seminars virtually.The attendees listened to the report on the work of ISO in 2024,reviewed and approved the membership fees in 2025,and elected the next ISO President and board members.The conference focused on global cooperation,sustainable development,and inclusivity in international standardization.展开更多
State Administration for Market Regulation and National Standardization Administration of China have approved the following 218 national standards and 1 national standard with amendment.
State Administration for Market Regulation and Standardization Administration of China have approved the following 6 mandatory national standards and 3 mandatory national standards with amendment.
基金supported by grants from the China Society for Drug Regulation(Grant No.2023-Y-Y-002)。
文摘The urgent need for effective cancer treatments,particularly for advanced and relapsed cases in which standard therapies are inadequate,has spurred the development of innovative therapeutic drugs1,2.Among the strategies to expedite drug development,the use of single-arm trials(SATs)is emerging as a promising avenue with substantial potential to shorten drug approval timelines and accelerate market entry.
文摘According to the official website of China’s National Medicines and Pharmaceutical Administration(NMPA),a total of 87 novel drugs were approved in China in 2023,with targeted drugs accounting for 67.8%of the total,amounting to 59 drugs(Fig.1a;Table 1)[https://www.nmpa.gov.cn/yaopin/ypjgdt/index.html].Notably,domestic innovation is flourishing,with five first-in-class drugs,including Glumetinib,a c-Met inhibitor from Haihe Biopharma;Leritrelvir,a 3CL protease inhibitor from Raynovent;Anaprazole,a proton pump inhibitor from Xuanzhu Biopharm;Pegol-Sihematide,an EPO drug from Hansoh Pharma;and Zuberitamab from BioRay Biopharmaceutical Co.,Ltd.Additionally,the world’s first allosteric inhibitor targeting TYK2,Sotyktu(deucravacitinib),has been approved for the treatment of psoriasis and Selumetinib,a MEK inhibitor co-developed by AstraZeneca and Merck Sharp&Dohme(MSD),became the first approved drug in China for the treatment of neurofibromatosis type I(NF1).Beyond these drugs,the approval of novel drug types such as CAR-T cell products,siRNA,monoclonal antibodies,dual antibodies,and ADCs in China is a significant development in the country’s pharmaceutical industry(Fig.1a).
基金funded by the FWO(1S34321N)the Fondation Charcot Stichting(to TV and RS)。
文摘Historically,"big pharma"did most central nervous system drug discovery R&D in-house.Yet,in modern times their"management reductionism"resulted in disappointing pipelines and pharma resided to(late)development,regulatory approval,and marketing(Thong,2015).This had significant consequences for financing and executing research,resulting in a larger role for funding by governments and patient-organizations and a shift of research to academia(Mazzucato,2013).
文摘Mongolia,a key partner in the Belt and Road Initiative,is fully dedicated to fostering regional cooperation and connectivity.Standardization has emerged as a vital field with far-reaching influence for regional trade cooperation.This paper makes an in-depth analysis of the standards approved in Mongolia in 2021 and 2022,offering a fresh perspective of the past two years’standardization development in the country.The primary objective is to present an updated account of Mongolia’s standardization efforts and to facilitate regional cooperation and exchange in standardization.
文摘The authors regret that the name of the ethic committee that approved the study and the reference number was omitted from the published paper.In this research,all animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals(US National Institutes of Healh)and were approved by the Animal Welfare and Ethical Committee of Hebei University(No.IACUC-2020XG021,Baoding,China).
文摘In the summer of 2023,two US restaurants added a novel item to their menus:chicken grown in a lab(Fig.1)[1,2].The first to receive regulatory approval for commercial sale,the lab-grown—or"cultivated"—meat starts as a few real chicken cells that are grown in vats of liquid and nutrients until they become pieces large enough to shape into nuggets and strips.
文摘The publisher would like to draw the reader's attention to the following errors.Ethics approval statements were not included in the published version of the following articles that appeared in previous issues of Grain&Oil Science and Technology.The authors were contacted after publication to request ethical approval statements for the following articles.
文摘State Administration for Market Regulation and National Standardization Administration of China have approved the following 328 national standards and 3 national standards with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 423 voluntary national standards and 2 national standards with amendment.
文摘State Administration for Market Regulation and National Standardization Administration of China have approved the following 258 national standards in foreign language version.
文摘State Administration for Market Regulation and National Standardization Administration of China have approved the following 24 mandatory national standards and 2 mandatory national standards with amendment.
文摘State Administration for Market Regulation and National Standardization Administration of China have approved the following 20 national standards and 1 national standard with amendment.
文摘The 46th Annual Meeting of ISO was held in Cartagena,Colombia.The event was attended by more than 700 representatives of ISO members,as well as international and regional organizations,with more than2,200 representatives participating in the series seminars virtually.The attendees listened to the report on the work of ISO in 2024,reviewed and approved the membership fees in 2025,and elected the next ISO President and board members.The conference focused on global cooperation,sustainable development,and inclusivity in international standardization.
文摘State Administration for Market Regulation and National Standardization Administration of China have approved the following 218 national standards and 1 national standard with amendment.
文摘State Administration for Market Regulation and Standardization Administration of China have approved the following 6 mandatory national standards and 3 mandatory national standards with amendment.
